Joyce_c
2021-03-18
Ok
3 Biotech Stocks to Avoid Right Now<blockquote>现在要避开的3只生物科技股</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
5
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":327185391,"tweetId":"327185391","gmtCreate":1616070327413,"gmtModify":1634527401713,"author":{"id":3572419380684882,"idStr":"3572419380684882","authorId":3572419380684882,"authorIdStr":"3572419380684882","name":"Joyce_c","avatar":"https://static.tigerbbs.com/faf0f288ddf8de4ed8f2127882064d27","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327185391","repostId":1142227040,"repostType":4,"repost":{"id":"1142227040","kind":"news","pubTimestamp":1616070253,"share":"https://www.laohu8.com/m/news/1142227040?lang=zh_CN&edition=full","pubTime":"2021-03-18 20:24","market":"us","language":"en","title":"3 Biotech Stocks to Avoid Right Now<blockquote>现在要避开的3只生物科技股</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142227040","media":"Motley Fool","summary":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newb","content":"<p> <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b> Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以大约每周一只的速度上市吗？这个领域有如此多的投资选择可供选择，令人有点惊讶的是，目前一些最受欢迎的公司在药物开发方面并没有取得多大成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者喜欢他们从这三个人那里听到的。不过，在随大流之前，您应该知道这些公司的成功之路充满了坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>该公司正在开发一种潜在的阿尔茨海默病新药，名为simufilam。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但对于这种进行性并最终致命的疾病，仍然没有任何可用的治疗方法。作为第一个，simufilam可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行第二阶段试验后，Cassava Sciences告诉投资者，美国食品和药物管理局(FDA)为定于今年下半年开始的两项第三阶段试验开了绿灯。如果simufilam在这两方面都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，Cassava Sciences已经开发simufilam十多年了，但仍然没有任何来自随机对照试验的证据表明simufilam按预期发挥作用。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年公布的一项小型二期研究中纳入了安慰剂组，但simufilam未能减少大脑沐浴液中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善情况。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2.Ocugen</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>由于一种名为科瓦克辛的COVID-19疫苗的好消息，这家临床阶段制药商的股价一直在飙升。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech已聘请Ocugen共同开发美国市场的科瓦克辛，看起来它是赢家。在一项有超过25,000名志愿者参与的3期研究中，科瓦克辛在预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何Ocugen股票之前，您应该知道，当COVID-19疫苗为零时，FDA不愿意在没有许多美国试验志愿者数据的情况下考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的3期试验，Ocugen在美国销售科瓦克辛的可能性为零。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3.Rubius Therapeutics</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这种临床阶段的生物技术正在开发新的癌症疗法，这些疗法由一系列红细胞制成，可以从货架上取下并在开出处方后立即使用。由于在一项针对多种癌症患者服用其主要候选药物RTX-240的早期研究中观察到一些肿瘤缩小，Rubius的股价今年飙升。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当好的结果，但对于Rubius的任何人来说，开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受最低测试剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics的红细胞经过精心设计，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和T细胞的扩增。不幸的是，该公司无法证明RTX-240为有反应的患者扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都拥有巨大的市场估值，如果他们的主导项目无法交付，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药处于临床试验中，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences有一种潜在的生物标志物新测试，可以指示阿尔茨海默病，但simufilam是其管道中唯一处于临床阶段的候选新药。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得FDA批准开始临床试验。如果这些公司中的任何一家在其主要候选人失败时有退路，那就是卢比乌斯。也就是说，目前考虑投资组合的风险仍然太大。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotech Stocks to Avoid Right Now<blockquote>现在要避开的3只生物科技股</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotech Stocks to Avoid Right Now<blockquote>现在要避开的3只生物科技股</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-03-18 20:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p> <b>Here's why these attention-grabbing stocks could be toxic to your portfolio.</b> Did you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.</p><p><blockquote><b>这就是为什么这些引人注目的股票可能对您的投资组合有害。</b>您知道新生物技术股票以大约每周一只的速度上市吗？这个领域有如此多的投资选择可供选择，令人有点惊讶的是，目前一些最受欢迎的公司在药物开发方面并没有取得多大成功。</blockquote></p><p> Every business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.</p><p><blockquote>每个企业都有一个故事要讲，很多投资者喜欢他们从这三个人那里听到的。不过，在随大流之前，您应该知道这些公司的成功之路充满了坑洼。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/98c795e31990a6c24ab59592b22abd7a\" tg-width=\"796\" tg-height=\"207\"><b>1. Cassava Sciences</b></p><p><blockquote><b>1.木薯科学</b></blockquote></p><p> This company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.</p><p><blockquote>该公司正在开发一种潜在的阿尔茨海默病新药，名为simufilam。在美国，65岁以上的人中有九分之一患有阿尔茨海默病，但对于这种进行性并最终致命的疾病，仍然没有任何可用的治疗方法。作为第一个，simufilam可能成为当时最畅销的药物之一。</blockquote></p><p> Following a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.</p><p><blockquote>在成功进行第二阶段试验后，Cassava Sciences告诉投资者，美国食品和药物管理局(FDA)为定于今年下半年开始的两项第三阶段试验开了绿灯。如果simufilam在这两方面都取得成功，这家生物技术公司的股价可能会飙升。</blockquote></p><p> Unfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.</p><p><blockquote>不幸的是，Cassava Sciences已经开发simufilam十多年了，但仍然没有任何来自随机对照试验的证据表明simufilam按预期发挥作用。</blockquote></p><p> The company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.</p><p><blockquote>该公司在去年公布的一项小型二期研究中纳入了安慰剂组，但simufilam未能减少大脑沐浴液中出现的炎症迹象。研究人员还对阿尔茨海默病患者进行了认知测试，看看simufilam是否真的产生了影响，但他们无法衡量改善情况。</blockquote></p><p> <b>2. Ocugen</b></p><p><blockquote><b>2.Ocugen</b></blockquote></p><p> Shares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.</p><p><blockquote>由于一种名为科瓦克辛的COVID-19疫苗的好消息，这家临床阶段制药商的股价一直在飙升。该疫苗的开发商Bharat Biotech是一家总部位于印度的知名疫苗制造商。</blockquote></p><p> Bharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.</p><p><blockquote>Bharat Biotech已聘请Ocugen共同开发美国市场的科瓦克辛，看起来它是赢家。在一项有超过25,000名志愿者参与的3期研究中，科瓦克辛在预防新冠肺炎感染方面的有效性约为81%。</blockquote></p><p> Before buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.</p><p><blockquote>在购买任何Ocugen股票之前，您应该知道，当COVID-19疫苗为零时，FDA不愿意在没有许多美国试验志愿者数据的情况下考虑紧急使用授权请求。既然该机构已经授权了三种安全有效的选择，那么如果没有新的3期试验，Ocugen在美国销售科瓦克辛的可能性为零。</blockquote></p><p> <b>3. Rubius Therapeutics</b></p><p><blockquote><b>3.Rubius Therapeutics</b></blockquote></p><p> This clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.</p><p><blockquote>这种临床阶段的生物技术正在开发新的癌症疗法，这些疗法由一系列红细胞制成，可以从货架上取下并在开出处方后立即使用。由于在一项针对多种癌症患者服用其主要候选药物RTX-240的早期研究中观察到一些肿瘤缩小，Rubius的股价今年飙升。</blockquote></p><p> In an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.</p><p><blockquote>在一项有16名志愿者数据的递增剂量试验的中期评估中，其中两名患者对RTX-240治疗反应良好。虽然对于早期试验的中期分析来说，这看起来是一个相当好的结果，但对于Rubius的任何人来说，开始庆祝可能还为时过早。这是因为迄今为止唯一确认的肿瘤缩小发生在接受最低测试剂量治疗的患者身上。</blockquote></p><p> Rubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.</p><p><blockquote>Rubius Therapeutics的红细胞经过精心设计，可以激发和招募不同类型的白细胞来对抗肿瘤。今年早些时候，该公司能够为八名患者展示自然杀伤细胞和T细胞的扩增。不幸的是，该公司无法证明RTX-240为有反应的患者扩增了这些抗肿瘤细胞。</blockquote></p><p> <b>Looking forward</b></p><p><blockquote><b>向前看</b></blockquote></p><p> All of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.</p><p><blockquote>所有这些公司目前都拥有巨大的市场估值，如果他们的主导项目无法交付，这些估值可能会崩溃。那是因为他们几乎没有什么可以依靠的。</blockquote></p><p> Ocugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.</p><p><blockquote>Ocugen目前没有任何潜在的新药处于临床试验中，我们还需要很长时间才能知道它打算开发的基因疗法是否有机会成功。Cassava Sciences有一种潜在的生物标志物新测试，可以指示阿尔茨海默病，但simufilam是其管道中唯一处于临床阶段的候选新药。</blockquote></p><p> Rubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.</p><p><blockquote>Rubius Therapeutics正在开发一个基于红细胞的治疗平台，该公司已经有第二个候选药物获得FDA批准开始临床试验。如果这些公司中的任何一家在其主要候选人失败时有退路，那就是卢比乌斯。也就是说，目前考虑投资组合的风险仍然太大。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RUBY":"Rubius Therapeutics, Inc.","SAVA":"Cassava Sciences Inc","OCGN":"Ocugen"},"source_url":"https://www.fool.com/investing/2021/03/18/3-biotech-stocks-to-avoid-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142227040","content_text":"Here's why these attention-grabbing stocks could be toxic to your portfolio.\n\nDid you know that newbiotech stocksgo public at a rate of about one per week? With so many investment options in this space to choose from, it's a little surprising that some of the most popular companies right now haven't had much success when it comes to drug development.\nEvery business has a story to tell, and plenty of investors like what they've been hearing from these three. Before following the crowd, though, you should know that there are potholes along these companies' paths to success.\n1. Cassava Sciences\nThis company's developing a potential new Alzheimer's disease drug called simufilam. In the U.S., 1 in 9 people over the age of 65 have Alzheimer's disease, but there still aren't any available treatments for this progressive and ultimately fatal disease. As the first, simufilam could become one of the top-selling drugs of its time.\nFollowing a successful phase 2 trial, Cassava Sciences told investors the Food and Drug Administration (FDA) gave the green light for a pair of phase 3 trials slated to begin in the second half of the year. If simufilam succeeds at both, shares of this biotech could explode higher.\nUnfortunately, Cassava Sciences has been developing simufilam for over a decade and it still doesn't have any evidence from a randomized controlled trial that simufilam works as intended.\nThe company included a placebo group in a smallphase 2study that read out last year, but simufilam failed to reduce signs of inflammation that show up in fluid that bathes the brain. Investigators also gave Alzheimer's disease patients cognitive tests to see if simufilam actually made a difference, but they couldn't measure an improvement.\n2. Ocugen\nShares of this clinical-stage drugmaker have been soaring in response to good news for a COVID-19 vaccine called Covaxin. The vaccine's developer, Bharat Biotech, is a well-established vaccine manufacturer headquartered in India.\nBharat Biotech has hired Ocugen to co-develop Covaxin for the U.S. market, and it looks like a winner. In a phase 3 study with over 25,000 volunteers, Covaxin was about 81% effective at preventing COVID-19 infections in India.\nBefore buying any Ocugen shares, you should know that the FDA wasn't willing to consider emergency use authorization requests without data from lots of U.S. trial volunteers when there were zero COVID-19vaccines available. Now that the agency has already authorized three safe and effective options, there's zero chance that Ocugen will sell Covaxin in the U.S. without a new phase 3 trial.\n3. Rubius Therapeutics\nThis clinical-stage biotech is developing new cancer therapies made from a line of red blood cells that can be taken off a shelf and administered as soon as they're prescribed. Shares of Rubius have soared this year, thanks to some tumor shrinkage observed in an early-stage study with a variety of cancer patients taking its lead candidate RTX-240.\nIn an interim assessment of an ascending-dosage trial that had data from 16 volunteers available, two of the patients have responded well to RTX-240 treatment. While this looks like a pretty good result for an interim analysis of an early trial, it's probably too early for anyone at Rubius to begin celebrating. That's because the only confirmed tumor shrinkage presented so far occurred for a patient treated with the lowest dosage tested.\nRubius Therapeutics' red blood cells are engineered to excite and enlist different types of white blood cells to take action against tumors. The company was able to show expansion of natural killer cells and T-cells for eight patients earlier this year. Unfortunately, the company hasn't been able to show RTX-240 expanded these tumor-fighting cells for the patients who responded.\nLooking forward\nAll of these companies have huge market valuations right now that could come crashing down if their lead programs can't deliver. That's because there's nearly nothing for them to fall back on.\nOcugen doesn't have any potential new drugs in clinical trials right now, and it's going to be a long time before we know if the gene therapies it intends to develop have a shot at success. Cassava Sciences has a potential new test for biomarkers that could indicate Alzheimer's disease, but simufilam is the only clinical-stage new drug candidate in its pipeline.\nRubius Therapeutics is developing a platform of red-blood-cell-based treatments, and the company already has a second candidate cleared by the FDA to begin clinical trials. If any of these companies has a fallback if its lead candidate doesn't work out, it's Rubius. That said, it's still way too risky to consider putting in your portfolio at the moment.","news_type":1,"symbols_score_info":{"RUBY":0.9,"SAVA":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1863,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/327185391"}
精彩评论